




Instance: composition-en-664d393693f4983d6c9e5af3f5904561
InstanceOf: CompositionUvEpi
Title: "Composition for uplizna Package Leaflet"
Description:  "Composition for uplizna Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/21/1602/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp664d393693f4983d6c9e5af3f5904561)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - uplizna"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Uplizna is and what it is used for  </li>
<li>What you need to know before you are given Uplizna  </li>
<li>How Uplizna is given  </li>
<li>Possible side effects  </li>
<li>How to store Uplizna  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What uplizna is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What uplizna is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Uplizna contains the active substance inebilizumab and belongs to a class of medicines called 
monoclonal antibodies. It is a protein that targets antibody-producing cells in the immune system (the 
body s natural defences) called B-cells. 
Uplizna is used to reduce the risk of attacks in adults with a rare condition called neuromyelitis optic 
spectrum disorder (NMOSD), which affects the nerves of the eye and spinal cord. The condition is 
thought to be due to the immune system mistakenly attacking the nerves in the body. Uplizna is given 
to patients with NMOSD whose B cells produce antibodies against aquaporin-4, a protein that plays an 
important role in nerve function.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take uplizna"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take uplizna"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Uplizna  </p>
<ul>
<li>if you are allergic to inebilizumab or any of the other ingredients of this medicine (listed in 
section 6). </li>
<li>if you are suffering from a severe active infection such as hepatitis B. </li>
<li>if you have active or untreated latent tuberculosis. </li>
<li>if you have a history of progressive multifocal leukoencephalopathy (PML), an uncommon but 
serious brain infection caused by a virus. </li>
<li>if you have been told that you have severe problems with your immune system. </li>
<li>if you have cancer. </li>
</ul>
<p>Warnings and precautions<br />
Talk to your doctor, pharmacist, or nurse before you are given Uplizna if you:</p>
<ul>
<li>have or think you have an infection. </li>
<li>have ever taken, take, or plan to take medicines that affect your immune system, or other 
treatments for NMOSD. These medicines could increase your risk of getting an infection. </li>
<li>
<p>have ever had hepatitis B or are a calirrier of the hepatitis B virus. </p>
</li>
<li>
<p>have had a recent vaccination or are scheduled to receive any vaccinations. You should receive 
any required vaccines at least 4 weeks before you start treatment with Uplizna. </p>
</li>
</ul>
<p>Infusion-related reactions 
Uplizna can cause infusion-related reactions, which can include headache, feeling sick (nausea), 
sleepiness, shortness of breath, fever, muscle pain, rash, or other symptoms. Treatment may be 
interrupted or stopped if symptoms occur. </p>
<p>Children and adolescents 
This medicine should not be given to children and adolescents because it has not been studied in this 
population. </p>
<p>Other medicines and Uplizna 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Pregnancy, breast-feeding and fertility<br />
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for 
advice before you are given this medicine. </p>
<p>Pregnancy 
Uplizna should not be used during pregnancy as the medicine may pass the placenta and affect the 
baby. If you are able to get pregnant you should use birth control (contraception) continuously once 
you start receiving Uplizna. If your doctor recommends stopping treatment, continue your 
contraception until 6 months after your last infusion.  </p>
<p>Breast-feeding 
It is not known if Uplizna passes into breast milk. If you are breast-feeding, talk to your healthcare 
provider about the best way to feed your baby if you start treatment with Uplizna. </p>
<p>Driving and using machines 
Uplizna is not expected to impact your ability to drive or use machines.  </p>
<p>Uplizna contains sodium<br />
This medicine contains 48 mg sodium (main component of cooking/table salt) in each infusion. This is 
equivalent to 2% of the recommended maximum daily dietary intake of sodium for an adult.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take uplizna"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take uplizna"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Uplizna is given by a drip (infusion) into a vein under the supervision of a doctor experienced in 
treating patients with NMOSD. </p>
<p>The recommended dose is 300 mg.  </p>
<p>The first dose is followed 2 weeks later by a second dose, and after that a dose every 6 months. </p>
<p>You will be given other medicines half an hour to an hour before the infusion, to reduce the risk of 
side effects. A doctor or nurse will monitor you during the infusion and for an hour afterward.  </p>
<p>If you have any further questions on the use of this medicine, ask your doctor. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Your 
doctor will discuss the possible side effects with you and explain the risks and benefits of Uplizna prior 
to treatment. </p>
<p>Serious side effects </p>
<p>The most serious side effects are infusion-related reactions and infections (see section 2). These side 
effects may happen any time during treatment or even after your treatment has ended. You may 
experience more than one side effect at the same time. If you have an infusion-related reaction or 
infection, call or see your doctor right away. </p>
<p>Other side effects </p>
<p>Very common (may affect more than 1 in 10 people) </p>
<ul>
<li>bladder infection </li>
<li>infection in the nose, throat, sinuses, and/or lungs </li>
<li>common cold </li>
<li>flu </li>
<li>joint pain </li>
<li>back pain </li>
<li>immunoglobulins decreased </li>
</ul>
<p>Common (may affect up to 1 in 10 people) </p>
<ul>
<li>lower-than-normal number white blood cells in the blood, sometimes occurring 4 weeks or more 
after the latest dose of Uplizna </li>
<li>swollen sinuses usually caused by an infection </li>
<li>pneumonia (lung infection) </li>
<li>cellulitis, a potentially serious bacterial skin infection </li>
<li>shingles (herpes zoster, a painful, blistering rash in one part of the body) </li>
<li>reaction to the Uplizna infusion (see Infusion-related reactions, above) </li>
</ul>
<p>Uncommon (may affect up to 1 in 100 people) </p>
<ul>
<li>infection in the blood (sepsis), an unusually severe response to an infection </li>
<li>progressive multifocal leukoencephalopathy (PML), an uncommon but serious brain infection 
caused by a virus </li>
<li>abscess (an infection under the skin usually caused by bacteria) </li>
<li>bronchiolitis, an infection of the airways caused by a virus </li>
</ul>
<p>Reporting of side effects  </p>
<p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects, you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store uplizna"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store uplizna"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.<br />
Do not use this medicine after the expiry date, which is stated on the carton after  EXP . The expiry 
date refers to the last day of that month. 
Store in a refrigerator at 2 C to 8 C. </p>
<p>Store in the original carton to protect from light. 
Do not freeze. 
Do not use this medicine if you notice particulate matter and discoloration. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Uplizna contains </p>
<ul>
<li>The active substance is inebilizumab. </li>
<li>Each vial contains 100 mg of inebilizumab. </li>
<li>The other ingredients are histidine, histidine hydrochloride monohydrate, polysorbate 80, 
sodium chloride, trehalose dihydrate, and water for injections. </li>
</ul>
<p>What Uplizna looks like and contents of the pack </p>
<p>Uplizna 100 mg concentrate for solution for infusion is a clear to slightly opalescent, colourless to 
slightly yellow solution supplied as one carton containing 3 vials.  </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Horizon Therapeutics Ireland DAC 
70 St. Stephen s Green 
Dublin 2 
D02 E2X4 
Ireland </p>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu. </p>         </div>"""      



Instance: composition-da-664d393693f4983d6c9e5af3f5904561
InstanceOf: CompositionUvEpi
Title: "Composition for uplizna Package Leaflet"
Description:  "Composition for uplizna Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/21/1602/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp664d393693f4983d6c9e5af3f5904561)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - uplizna"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du begynder at få Uplizna  </li>
<li>Sådan gives Uplizna </li>
<li>Bivirkninger  </li>
<li>Opbevaring  </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What uplizna is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What uplizna is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Uplizna indeholder det aktive stof inebilizumab og tilhører en gruppe lægemidler kaldet monoklonale 
antistoffer. Det er et protein, som går efter celler i immunsystemet (kroppens naturlige forsvar), som 
producerer antistoffer, kaldet B-celler. 
Uplizna bruges til at nedbringe risikoen for attakker hos voksne med en sjælden tilstand kaldet 
neuromyelitis optica spektrumforstyrrelse (NMOSD), som berører nerverne i øjet og rygmarven. 
Tilstanden menes at forekomme, fordi immunsystemet ved en fejl angriber kroppens nerver. Uplizna 
gives til patienter med NMOSD, hvis B-celler producerer antistoffer mod aquaporin-4, et protein, der 
spiller en vigtig rolle i nervernes funktion.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take uplizna"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take uplizna"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Uplizna  </p>
<ul>
<li>hvis du er allergisk over for inebilizumab eller et af de øvrige indholdsstoffer i dette 
lægemiddel (angivet i afsnit 6). </li>
<li>hvis du har en alvorlig aktiv infektion såsom hepatitis B. </li>
<li>hvis du har aktiv eller ubehandlet latent tuberkulose. </li>
<li>hvis du har en sygehistorie med progressiv multifokal leukoencefalopati (PML), en usædvanlig 
men alvorlig hjerneinfektion forårsaget af en virus. </li>
<li>hvis du har fået at vide, at du har alvorlige problemer med dit immunsystem. </li>
<li>hvis du har kræft. </li>
</ul>
<p>Advarsler og forsigtighedsregler<br />
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du får Uplizna, hvis du:</p>
<ul>
<li>
<p>har eller tror, at du har en infektion. </p>
</li>
<li>
<p>nogensinde har tager, tager eller planlægger at tage medicin, der påvirker dit immunsystem, 
eller andre behandlinger for NMOSD. Disse lægemidler kan øge din risiko for at få en infektion. </p>
</li>
<li>nogensinde har haft hepatitis B eller er bærer af hepatitis B-virus. </li>
<li>har fået en vaccination for nylig eller har planlagt at få en vaccination. Du skal have eventuelle 
påkrævede vacciner mindst 4 uger, før du påbegynder behandling med Uplizna. </li>
</ul>
<p>Infusionsrelaterede reaktioner 
Uplizna kan forårsage infusionsrelaterede reaktioner, som kan omfatte hovedpine, utilpashed 
(kvalme), søvnløshed, åndenød, feber, muskelsmerter, udslæt eller andre symptomer. Behandlingen 
kan blive afbrudt eller stoppet, hvis du får symptomer. </p>
<p>Børn og unge 
Dette lægemiddel bør ikke gives til børn og unge, da det ikke er blevet undersøgt i denne population. </p>
<p>Brug af anden medicin sammen med Uplizna 
Fortæl lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden medicin 
eller planlægger at tage anden medicin. </p>
<p>Graviditet, amning og frugtbarhed<br />
Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge 
din læge til råds, før du får dette lægemiddel. </p>
<p>Graviditet 
Uplizna bør ikke anvendes under graviditeten, da dette lægemiddel kan passere placenta og påvirke 
barnet. Hvis du er i stand til at blive gravid, skal du anvende prævention (kontraception) kontinuerligt, 
efter du begynder at få Uplizna. Hvis din læge anbefaler at stoppe behandlingen, skal du fortsætte med 
at bruge prævention indtil 6 måneder efter din sidste infusion.  </p>
<p>Amning 
Det er ukendt, om Uplizna udskilles i human mælk. Hvis du ammer, skal du tale med in læge om den 
bedste måde at ernære dit barn, hvis du påbegynder behandling med Uplizna. </p>
<p>Trafik- og arbejdssikkerhed 
Uplizna forventes ikke at påvirke din evne til at føre motorkøretøj eller betjene maskiner.  </p>
<p>Uplizna indeholder natrium<br />
Dette lægemiddel indeholder 48 mg natrium (hoved komponent af madlavnings-/bordsalt) i hver 
infusion.  Dette svarer til 2 % af den anbefalede maximale daglige indtagelse af natrium for en voksen.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take uplizna"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take uplizna"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Uplizna gives som et drop (infusion) i en vene under overvågning af en læge med erfaring i 
behandling af patienter med NMOSD. </p>
<p>Den anbefalede dosis er 300 mg.  </p>
<p>Den første dosis efterfølges 2 uger senere af en anden dosis, og derefter en dosis hver 6. måned. </p>
<p>Du vil få anden medicin en halv til en hel time før infusionen for at reducere risikoen for bivirkninger. 
Du vil blive overvåget af en læge eller sygeplejerske under infusionen og i en time bagefter.  </p>
<p>Spørg lægen, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. Din 
læge vil tale med dig om mulige bivirkninger og forklare risici og fordele ved Uplizna før 
behandlingen. </p>
<p>Alvorlige bivirkninger </p>
<p>De mest alvorlige bivirkninger er infusionsrelaterede reaktioner og infektioner (se afsnit 2). Disse 
bivirkninger kan forekomme når som helst i løbet af behandlingen, eller selv efter behandlingen er 
slut. Du kan få mere end én bivirkning på samme tid. Hvis du får en infusionsrelateret reaktion eller 
infektion, skal du kontakte din læge med det samme. </p>
<p>Andre bivirkninger </p>
<p>Meget almindelig (kan berøre mere end 1 ud af 10 personer) </p>
<ul>
<li>blærebetændelse </li>
<li>infektion i næse, svælg, bihuler og/eller lunger </li>
<li>almindelig forkølelse </li>
<li>influenza </li>
<li>ledsmerter </li>
<li>rygsmerter </li>
<li>fald i immunglobuliner </li>
</ul>
<p>Almindelig (kan berøre op til 1 ud af 10 personer) </p>
<ul>
<li>færre hvide blodlegemer end normalt, som sommetider forekommer 4 uger eller mere efter den 
sidste dosis Uplizna </li>
<li>hævede bihuler, som normalt skyldes en infektion </li>
<li>lungebetændelse </li>
<li>cellulitis, en potentielt alvorlig bakterieinfektion i huden </li>
<li>helvedesild (herpes zoster, et udslæt med smertefulde blærer på en kropsdel) </li>
<li>reaktion over for infusion med Uplizna (se infusionsrelaterede reaktioner ovenfor) </li>
</ul>
<p>Ikke almindelig (kan berøre op til 1 ud af 100 personer) </p>
<ul>
<li>infektion i blodet (sepsis), et usædvanligt voldsomt respons på en infektion </li>
<li>progressiv multifokal leukoencefalopati (PML), en usædvanlig men alvorlig hjerneinfektion 
forårsaget af en virus </li>
<li>byld (en infektion under huden, som normalt skyldes en bakterie) </li>
<li>bronkitis, en infektion i luftvejene forårsaget af en virus </li>
</ul>
<p>Indberetning af bivirkninger  </p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken.  Det 
gælder også mulige  bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine 
pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale 
rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at 
fremskaffe mere information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store uplizna"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store uplizna"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.<br />
Brug ikke lægemidlet efter den udløbsdato, der står på æsken efter EXP. Udløbsdatoen er den sidste 
dag i den nævnte måned. </p>
<p>Opbevares i køleskab ved 2 °C til 8 °C. 
Opbevares i den originale yderpakning for at beskytte mod lys. 
Må ikke fryses. 
Brug ikke lægemidlet, hvis du bemærker partikler og misfarvning. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Uplizna indeholder:</p>
<ul>
<li>Aktivt stof: inebilizumab. </li>
<li>Hvert hætteglas indeholder 100 mg inebilizumab. </li>
<li>Øvrige indholdsstoffer: histidin, histidin-hydrochloridmonohydrat, polysorbat 80, 
natriumchlorid, trehalosedihydrat og vand til injektionsvæske. </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Uplizna 100 mg koncentrat til infusionsvæske, opløsning er en klar til let opaliserende, farveløs til let 
gul opløsning, der fås i en æske med 3 hætteglas.  </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Horizon Therapeutics Ireland DAC 
70 St. Stephen’s Green 
Dublin 2 
D02 E2X4 
Irland </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-664d393693f4983d6c9e5af3f5904561
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for uplizna Package Leaflet for language en"
Description: "ePI document Bundle for uplizna Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-664d393693f4983d6c9e5af3f5904561"
* entry[0].resource = composition-en-664d393693f4983d6c9e5af3f5904561

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp664d393693f4983d6c9e5af3f5904561"
* entry[=].resource = mp664d393693f4983d6c9e5af3f5904561
                            
                    
Instance: bundlepackageleaflet-da-664d393693f4983d6c9e5af3f5904561
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for uplizna Package Leaflet for language da"
Description: "ePI document Bundle for uplizna Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-664d393693f4983d6c9e5af3f5904561"
* entry[0].resource = composition-da-664d393693f4983d6c9e5af3f5904561

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp664d393693f4983d6c9e5af3f5904561"
* entry[=].resource = mp664d393693f4983d6c9e5af3f5904561
                            
                    



Instance: mp664d393693f4983d6c9e5af3f5904561
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Uplizna 100 mg concentrate for solution for infusion"
Description: "Uplizna 100 mg concentrate for solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1602/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Uplizna 100 mg concentrate for solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 664d393693f4983d6c9e5af3f5904561ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "uplizna"

* status = #current
* mode = #working

* title = "List of all ePIs associated with uplizna"

* subject = Reference(mp664d393693f4983d6c9e5af3f5904561)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#uplizna "uplizna"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-664d393693f4983d6c9e5af3f5904561) // uplizna en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-664d393693f4983d6c9e5af3f5904561) // uplizna da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-664d393693f4983d6c9e5af3f5904561
InstanceOf: List

* insert 664d393693f4983d6c9e5af3f5904561ListRuleset
    